JP2010174028A - Intraorally soluble or chewing solid internal pharmaceutical composition containing bitter agent - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide an intraorally soluble or chewing solid internal pharmaceutical composition which contains a bitter agent and is easy to take. <P>SOLUTION: The intraorally soluble or chewing solid internal pharmaceutical composition contains the bitter agent and 0.1-2.25 wt.% of a menthol. Preferably, the bitter agent includes chlorpheniramine maleate, phenylpropanolamine hydrochloride, belladonna total alkaloid, anhydrous caffeine, mequitazine, ketotifen fumarate, cimetidine, aldioxa, famotidine, carrot powder, etc. <P>COPYRIGHT: (C)2010,JPO&INPIT

Description

  The present invention relates to a dissolved or chewable solid internal medicine composition that can be easily taken.

  In recent years, the necessity of improving the quality of life (QOL) has been emphasized. In the medical field, in connection with improvement of patient QOL, in addition to safety and effectiveness, medicines are required to be easy to take. Conventionally, it has been a matter of course for patients to take patience even if they are bitter or difficult to take. However, in the case of a medicine that imposes a burden on the patient when taking such medicine, there is a possibility that the medication instruction may not be observed and an appropriate therapeutic effect may not be obtained. Therefore, if the drug efficacy is the same, it is desirable to use a preparation that is easy to take, not only to reduce the burden on the patient, but also to improve compliance (compliance) and achieve the expected therapeutic effect. Of course it is natural. For these reasons, it is necessary to provide a pharmaceutical preparation that is easy to take not only for the patient's QOL but also for improving compliance and performing appropriate treatment.

Conventional solid internal medicine must be taken with a large amount of water or hot water, and is difficult to take for elderly people or patients who cannot get up. In addition, there is a problem that it is difficult to follow the instructions even when water is not readily available. On the other hand, if it is a solid preparation in the mouth or chewable, it can be easily taken even by an elderly person and can be taken in any posture. And since water is unnecessary, taking time can be reliably protected irrespective of the presence or absence of water. However, these types of preparations that are gradually dissolved or chewed in the mouth have a long residence time in the mouth, so if they contain a drug with an unpleasant stimulus typified by bitterness, dosing instructions It is difficult to protect.
However, since many drugs have an unpleasant taste or irritation such as bitterness, acidity, and astringency, there are limitations on the drugs that can be applied to the oral dissolution type or chewing type preparations.

Conventionally, as a method for masking the bitterness of a certain medicinal component, a method of physically adsorbing a carrier, a method of microencapsulating a medicinal component or a coating method are known. However, these methods have a problem that the preparation tends to be large, the gastrointestinal absorption inhibition of the medicinal component by the carrier or the coating occurs, and the preparation process is complicated.
In addition, there is a method of adding a sweetener or a corrigent to a medicinal ingredient, but the type of discomfort (bitterness, sourness, astringency, etc.) differs for each drug, and the bitterness threshold value is different. For this reason, bitterness and the like may not be sufficiently suppressed, and the masking effect is not always sufficient.

  Furthermore, as long as it is a solid preparation for internal use, it has excellent properties in terms of in-vivo behavior of the drug, such as release, absorption and expression of effects in the digestive tract, apart from ease of taking and elimination of unpleasant taste. Must be. For example, menthol is often blended for the purpose of giving a refreshing or refreshing feeling to a solid pharmaceutical composition. However, as the blending amount increases, (1) the bitterness of the preparation is enhanced because of its own bitterness. It is known that there are disadvantages such as (2) hindering drug elution from the preparation and consequently reducing the drug efficacy; or (3) precipitating whiskers during storage. . Conventionally, in order to avoid such inconvenience, it has been necessary to suppress the amount of menthol to a small amount, and the usual amount was less than 0.1% by weight. Thus, it was thought that increasing the amount of menthol to mask the bitter taste of the drug was harmful.

The inventors of the present invention have intensively and intensively studied for the purpose of providing an effective solid pharmaceutical composition that is easy to take and has a simple manufacturing process, and as a result, a specific amount of menthol in a mouth-dissolving or mouth-masticating solid preparation. It was found that the unpleasant taste of the drug was improved and the properties of the preparation and the expression of the drug effect were not affected, and the present invention was completed.
That is, the present invention provides a solid pharmaceutical composition of the mouth-dissolving type or chewing type containing a drug having a bitter taste and 0.1 to 2.25% by weight of menthol.

Accordingly, the present invention provides the following.
(1) A mouth-dissolving or chewing type solid oral pharmaceutical composition containing a drug having a bitter taste and 0.1 to 2.25% by weight of menthol.
(2) The pharmaceutical composition according to item (1), wherein the amount of menthol is 1.0 to 2.0% by weight.
(3) The pharmaceutical composition according to item (1), wherein the menthol content is 0.5 to 2.0% by weight.
(4) The pharmaceutical composition according to any one of items (1) to (3), wherein the amount of menthol per dose is 2 to 9 mg.
(5) Items in which the bitter tasting drug is selected from CNS stimulants, antihistamines / antiallergic drugs, parasympathomimetic drugs, sympathomimetic drugs, crude drugs, antitussives, antipyretic analgesics and antacids The pharmaceutical composition according to any one of (1) to (4).
(6) The pharmaceutical composition according to any one of items (1) to (5), which is a mouth chewable preparation.

The “in-mouth dissolved or chewable solid pharmaceutical composition” of the present invention refers to a preparation to be taken in the mouth in the presence of saliva in an instant or gradually dissolved form, or by chewing, pulverizing and mixing with saliva. It is a preparation to be taken after part or all is dissolved.
In addition, the “drug having a bitter taste” means that it is difficult for a human having a normal sensation to take it by chewing or dissolving in the mouth from the viewpoint of improving patient compliance, which is one of the objects of the present invention. It refers to drugs with an unpleasant taste that feels resistance, including not only drugs with literal bitterness but also drugs with stimulating tastes such as astringency and acidity, and the type of drug is not particularly limited . Also included in this definition are drugs that have undergone treatments such as bitterness masking and coating to control drug dissolution rate.

As shown in the test examples described later, the mouth-dissolving or chewing type pharmaceutical composition of the present invention is appropriately masked for the bitter taste of the drug, and is stable for a long time without the occurrence of whiskers. Unexpectedly, although the composition of the present invention contains a large amount of menthol having its own bitter taste, the bitter taste of the drug is masked and is easy to take, and the disintegration and dissolution of the drug is also good. . As described above, the composition of the present invention is effective in improving compliance, is excellent in elution and absorption in the digestive tract after administration, and achieves a predetermined drug behavior and exhibits a sufficient pharmacological effect. It is an excellent formulation that can be made.
Improvement in dissolution performance reaches the digestive tract in a state where it is well mixed with saliva in the mouth and promotes dissolution, reaches the absorption site in a state where it is easily absorbed as a mixture with saliva, maintains the stability, and maintains the stability. Related to being absorbed from. Therefore, according to the present invention, it is possible to achieve an unexpectedly superior therapeutic effect as compared to taking the same amount of drug as an internal tablet without dissolving or chewing in the mouth.

  In the present invention, since the menthol and the drug can directly enhance the drug therapeutic effect by directly acting on the nasal mucosa and bronchial mucosa, among the drugs exhibiting bitter taste, in particular, the drug for treating nasal inflammation and the drug for treating respiratory symptoms It is more preferable to contain. It is also preferable to contain a gastrointestinal therapeutic drug because the refreshing feeling of menthol is effective in removing upset stomach.

  The menthol used in the present invention is described in the literature (13th revised Japanese Pharmacopoeia, D1050 to 1058), and it is also possible to use a commercially available product, either a natural essential oil or a synthetic product. Can do. The menthol of the present invention may be either l-form or dl-form. Furthermore, essential oils containing menthol such as peppermint oil, mint oil, and spare mint oil are also included in the menthol of the present invention. When menthol is used in the composition of the present invention in the range of 0.1 to 2.25% by weight, it provides a refreshing refreshing feeling without bitterness and is effective for improving patient compliance. Beyond this range, menthol stimulation can be uncomfortable. On the other hand, if it is less than this range, the bitterness of the drug may not be sufficiently masked.

The amount of menthol in the composition of the present invention is suitably in the range of 0.1 to 2.25% by weight as described above. When used in this range, the bitter taste of the drug can be masked, whisker expression can be avoided, and a stable composition can be obtained. However, in order to more fully achieve the avoidance of whisker expression and the masking effect, the amount of menthol is preferably 0.5 to 2.0% by weight, and 1.0% to 2.0% by weight. It is more preferable.
The composition of the present invention is produced so that the single dose of adult menthol is in the range of 2-9 mg, preferably 3-9 mg, more preferably 4-9 mg. The daily dose for adults is 6 to 27 mg, preferably 9 to 27 mg, more preferably 12 to 27 mg.

The pharmaceutical composition of the present invention may contain an arbitrary “drug having a bitter taste” in an amount defined for each drug.
Such drugs include CNS stimulants, antihistamines / antiallergic drugs, parasympathetic blockers, sympathomimetic drugs (vasoconstrictors), anti-inflammatory enzymes, anti-inflammatory drugs, herbal medicines, antitussives, expectorants, sputum dissolution Examples include drugs, antipruritics, antipyretic analgesics, antacids, mucosal repair agents, intestinal preparations, gastric agents, digestives, analgesic antispasmodics, antipruritics and the like. Among them, there are drugs that exhibit bitter taste as exemplified below in central nerve stimulants, antihistamines / antiallergic drugs, parasympathetic blockers, sympathomimetics, herbal medicines, antitussives, antipyretic analgesics and antacids. It is known and preferably used in the composition of the present invention.

Examples of the central nervous stimulant include caffeine, and specific examples include anhydrous caffeine, caffeine, sodium benzoate caffeine and the like.
Antihistamines and antiallergic agents include isothipentyl hydrochloride, promethazine hydrochloride, promethazine methylene disalicylate, carbinoxamine, astemizole, clemastine fumarate, mequitazine, chlorpheniramine maleate, diphenhydramine hydrochloride, diphenhydramine salicylate, diphenhydramine tanninate, diphenhydramine, Examples include amlexanox, cyproheptadine, ketotifen fumarate, alimemazine tartrate, tranilast, pemirolast potassium, azelastine hydrochloride, oxatomide, emedastine fumarate, epinastine hydrochloride, and salts thereof.

Examples of parasympathetic nerve blockers include datsura extract, belladonna alkaloid, belladonna total alkaloid, belladonna extract, funnel extract, and isopropamide iodide.
Examples of sympathomimetic drugs include phenylpropanolamine hydrochloride, phenylephrine hydrochloride, methylephedrine hydrochloride, ephedrine hydrochloride, methoxyphenamine hydrochloride, norepinephrine, naphazoline nitrate, gyrometazoline, middolin, methoxamine, tetrahydrozoline, and their salts. It is done.

  Herbal medicines include aloe, fennel, turmeric, yak, engosaku, ages, ogi, seisei, onji, guarana, kukosi, jiou, touki, eucommia, carrot, amarogentin, ougon, okaku, ouren, gajutsu, caskara sagrada, cuckoo, Cascarilla, cypress grass, carroton, cypress, pheasant, kyonin, yellowfin, wolfberry, kujin, keigai, keihi, ketsumeishi, kengoshi, gentiana, gennoshouko, koujin, kobushi, koboku, burdock, gosh, goshyu, garsh, colander , Sansushi, Saffron, Sandscon, Giant, Sicon, Sisoshi, Peonies, Shajin (Tsuriganeninjin), Shazen (Psyllium), Jia incense, Showa, Shouma, Sehi, Sekishokon, Se Cucumber, centipede, centaurium grass, assembly, senbo, senso, senna, sagetsu, sakuhakuhi, soyou, daiou, bamboo ginseng, chimo, chiletta grass, chimpi, spruce, tonin, tokon, nigaki, carrot, peony, peanut, belladonnackon, Examples include henoposi oil, yakchi, yutan, mugwort, mugwort, bitter tincture, jishyu, hop, homika, bowie, maou, mokutsu, mokko, ryutan, gentian, luzonka, forsythia and the like.

Antitussives include dextromethorphan hydrobromide, dextromethorphan, noscapine hydrochloride, noscapine, methylephedrine hydrochloride, phenylpropanolamine hydrochloride, methoxyphenamine hydrochloride, and the like.
Examples of expectorants include bromhexine hydrochloride and ambroxol hydrochloride.

Examples of antipyretic analgesics include aspirin, aspirin aluminum, acetaminophen, etenzamide, salicylamide, ibuprofen, phenacetin, diclofenac sodium, pranoprofen and the like.
Examples of the antacid include H ₂ receptor antagonists such as cimetidine, ranitidine, and famotidine.
The above drugs are merely examples, and it will be apparent to those skilled in the art that drugs having any bitter taste can be included in the composition of the present invention as long as they meet the purpose of the present invention.

The composition of the present invention can contain a drug suitable for the treatment of any disease, but since it is a mouth-dissolving or chewable preparation, it directly acts on the nasal cavity, oral cavity, respiratory tract, etc. at these sites. It is preferable to contain a drug effective for a disease because immediate action and sustained action can be obtained.
The compounding amount of these drugs is appropriately blended at a commonly used dose. Furthermore, the composition of the present invention may contain a drug other than a drug having a bitter taste. In addition, minerals, vitamins, amino acids and the like can be blended as necessary.

The pharmaceutical composition of the present invention may be in any dosage form as long as it is in a form that can be taken by dissolving or chewing in the mouth, and tablets (plain tablets, dragees), candy (pox), gummi, nougat Etc. are exemplified. The shape and size are appropriately selected as long as there is no inconvenience for taking in the mouth. In production, a known method used in the case of producing a composition having the same form in the technical field may be used as it is or by appropriately applying it.
Tablets are prepared by mixing powdered drugs and pharmaceutically acceptable excipients and compression-molding. Also, candy (gummy), gummi, nougat, etc. can be prepared by methods known in the confectionery field. Can be prepared.
For example, the tablet may be an extrusion granulation method, a pulverization granulation method, a dry compaction granulation method, a fluidized bed granulation method, a rolling granulation method, a high-speed stirring granulation method, a wet tableting method known in the art. What is necessary is just to manufacture combining a direct tableting method etc. suitably according to the objective.
A preferred dosage form for the practice of the present invention is a tablet, in particular a chewable tablet in the mouth.

  Any component that is generally used as a pharmaceutical additive can be added to the preparation of the present invention as long as the effect of the present invention is not affected. Such additives include corn starch, potato starch, sucrose, talc, kaolin, calcium sulfate, calcium carbonate, excipients such as crystalline cellulose, lubricants such as magnesium stearate, calcium stearate, carboxymethylcellulose calcium, Disintegrants such as low-substituted hydroxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, gelatin, cellulose polymer, acrylic polymer, methylcellulose, gum arabic, polyvinyl alcohol, and other sweeteners, Examples include flavoring agents, coloring agents, flavoring agents, adsorbents, preservatives, wetting agents, and antistatic agents.

日本薬局方 製剤総則「錠剤」に準じて、錠剤を製した。具体的には、ｄ−マレイン酸クロルフェニラミンからマンニットまでの成分をとり、湿式造粒法により、顆粒（A）を調製する。他方、メントールとアビセルを混合して、メントール倍散（B）を調製する。次に、顆粒（A）、メントール倍散（B）、及びステアリン酸マグネシウムを混合して、打錠用顆粒とし、これを重量４００ｍｇ／錠ととして、打錠機でチュアブル錠を製した。実施例１の咀嚼錠のメントール含量は、１.０重量％であり、１日量にして１２mgである。実施例２の咀嚼錠のメントール含量は２.０重量％であり、１日量にして２４mgである。 Hereinafter, the present invention will be described in more detail with reference to examples.
Examples 1-2 Tablet

According to the Japanese Pharmacopoeia General Rules for Tablets “Tablets”, tablets were produced. Specifically, the components from d-chlorpheniramine maleate to mannitol are taken, and granules (A) are prepared by a wet granulation method. On the other hand, menthol doubling (B) is prepared by mixing menthol and Avicel. Next, the granules (A), menthol trituration (B), and magnesium stearate were mixed to form tablets for tableting, and the weight was set to 400 mg / tablet, and chewable tablets were produced with a tableting machine. The chewable tablet of Example 1 has a menthol content of 1.0% by weight and a daily dose of 12 mg. The chewable tablet of Example 2 has a menthol content of 2.0% by weight and a daily dose of 24 mg.

実施例１と同様に、メキタジンからマンニットまでの成分を用いて顆粒（A）を調製し、他方、アビセルからミントオイル又はハッカ油までの成分を混合して、メントール倍散（B）を調製し、１錠５００ｍｇの錠剤を製した。 Example 3 Tablet

As in Example 1, granules (A) were prepared using ingredients from mequitazine to mannitol, while ingredients from Avicel to mint oil or mint oil were mixed to prepare menthol trituration (B). One tablet of 500 mg was made.

実施例１と同様に、フマル酸ケトチフェンからソルビットまでの成分を用いて顆粒（Ａ）を調製し、他方、Ｌ−ＨＰＣとメントールからメントール倍散（B）を調製し、１錠２５０ｍｇの錠剤を製した。 Example 4 Tablet

As in Example 1, granules (A) were prepared using components from ketotifen fumarate to sorbit, while menthol trituration (B) was prepared from L-HPC and menthol. Made.

実施例１と同様に、シメチジンからマンニットまでの成分を用いて顆粒（A）を調製し、他方、アビセルからメントールまでの成分を混合して、メントール倍散（B）を調製し、１錠４００ｍｇの錠剤を製した。 Example 5 Tablet

As in Example 1, granules (A) were prepared using ingredients from cimetidine to mannitol, while ingredients from Avicel to menthol were mixed to prepare menthol trituration (B), 1 tablet 400 mg tablets were made.

実施例１と同様に、ファモチジンからマンニットまでの成分を用いて顆粒（Ａ）を調製し、他方、他方、アビセルからメントールまでの成分を混合して、メントール倍散（B）を調製し、１錠４００ｍｇの錠剤を製した。 Example 6 Tablet

As in Example 1, granules (A) were prepared using ingredients from famotidine to mannitol, while the ingredients from Avicel to menthol were mixed to prepare menthol trituration (B), One tablet of 400 mg was produced.

Test Example 1 Dissolution Test Using the tablets of Examples 1 and 2, a test was conducted according to the dissolution test method (paddle method) which is a general test method of the Japanese Pharmacopoeia. As the test solution, a test solution having a pH of 1.2 assuming a gastric juice in a disintegration test which is a general test method of the Japanese Pharmacopoeia or a pH 6.8 assuming an intestinal fluid was used.
The test was performed in 500 ml of the test solution at 37 ° C. and a paddle rotation speed of 100 rpm. Each tablet was chewed about 5 to 15 times in the mouth and then added to the test solution as a sample. After starting the test, the eluate was collected over time, and the drug elution amount was measured using chlorpheniramine maleate blended in the chewable tablet as an indicator component. Chlorpheniramine maleate was measured by a conventional HPLC method. The results are shown in Table 6.

表６から、それぞれ、１.０%、及び２.０%のメントールを含有する実施例１及び２のチュアブル錠からの薬物の溶出は、メントールによる阻害を受けていないことが分かる。薬物の溶出は素早く、しかも短時間で完全溶出を示しており試験溶液のｐＨにも左右されていない。この結果は指標成分であるマレイン酸クロルフェニラミン以外の他の成分である、塩酸フェニルプロパノールアミン、ベラドンナ総アルカロイドに関しても同様であった。
薬物放出速度とその変動は、消化管内での薬物吸収の速度、吸収量と密接に関連しており、薬物治療の効果の発現に大きい影響を及ぼすことが知られている。上記の試験結果は、本発明の製剤が従来の製剤に比較して優れた溶出速度を示すものであることを明らかにし、本発明製剤が即効性であると同時に生物学的利用率が高く、確実に持続して高い効果を発揮しうる有用な製剤であることを証明するものである。

From Table 6 it can be seen that the dissolution of the drug from the chewable tablets of Examples 1 and 2 containing 1.0% and 2.0% menthol, respectively, was not inhibited by menthol. Elution of the drug is quick and complete in a short time and does not depend on the pH of the test solution. The results were the same for phenylpropanolamine hydrochloride and belladonna total alkaloids other than the indicator component chlorpheniramine maleate.
It is known that the drug release rate and its variation are closely related to the rate and amount of drug absorption in the gastrointestinal tract, and have a great influence on the manifestation of the effect of drug treatment. The above test results reveal that the preparation of the present invention exhibits an excellent dissolution rate as compared with the conventional preparation, and the preparation of the present invention has an immediate effect and a high bioavailability, It proves that it is a useful preparation that can reliably and sustainably exhibit high effects.

鼻炎症状（くしゃみ、鼻水、鼻づまり、のどの痛み、涙目、頭重）の治療効果を、表７に示す試験薬剤を用いて試験した。一方、胃痛、胃のむかつき等に対する治療効果を、表8に示す試験薬剤を用いて試験した。試験薬剤の調製は実施例１に記載の方法に従って行った。
これらの製剤は、いずれも、含量試験、崩壊試験（ＪＰ）、含量均一性試験（ＪＰ）に適合することを確認した。
鼻炎症状（くしゃみ、鼻水、鼻づまり、のどの痛み、涙目、頭重）を有する被験者１４名に薬剤Ａ〜Ｄを投与（一回一錠）し、症状の改善度を、薬剤服用１０分後と４時間後に評価した。同様に、胃痛、胃のむかつきを訴える被験者１０名に薬剤Ｅ、Ｆを投与（一回一錠）し、症状の改善度を、薬剤服用１０分後と４時間後に評価した。
咀嚼剤Ａ、Ｂ、Ｅ、Ｆ、は口中で咀嚼（５から１５回）して服用し、溶解剤Ｃは咀嚼せず口中で溶解させ、服用した。また、錠剤Ｄは、１５０ｍｌの水で、口中で咀嚼又は溶解せずに内服した。試験結果を表９及び表１０に示す。 Test Example 2 Effectiveness test

The therapeutic effects of nasal inflammation symptoms (sneezing, runny nose, nasal congestion, sore throat, tear eyes, head weight) were tested using the test agents shown in Table 7. On the other hand, therapeutic effects on gastric pain, upset stomach, etc. were tested using the test drugs shown in Table 8. The test drug was prepared according to the method described in Example 1.
All of these preparations were confirmed to meet the content test, disintegration test (JP), and content uniformity test (JP).
14 subjects with nasal inflammation (sneezing, runny nose, stuffy nose, sore throat, tear eyes, head weight) were administered drugs A to D (one tablet at a time), and the degree of improvement in symptoms was 10 minutes after taking the drug. And evaluated after 4 hours. Similarly, drugs E and F were administered to 10 subjects complaining of stomach pain and upset stomach (one tablet at a time), and the degree of symptom improvement was evaluated 10 minutes and 4 hours after taking the drug.
Chewing agents A, B, E and F were chewed (5 to 15 times) in the mouth and taken, and dissolving agent C was dissolved in the mouth without being chewed. Tablet D was taken with 150 ml of water without being chewed or dissolved in the mouth. The test results are shown in Table 9 and Table 10.

The chewable and soluble preparations A, C and E of the present invention are effective in improving nasal inflammation or stomach pain and upset stomach as well as chewable preparations B and F not containing menthol. It shows the improvement rate. In particular, the immediate effect of the preparation of the present invention is much higher than that of the respective control preparations B and F, and it is shown that the immediate effect is remarkably enhanced when menthol is contained in the chewable or dissolved preparation.
These results also mean that the presence of a large amount of menthol does not affect the effects of rhinitis and gastrointestinal symptoms, but rather increases immediate efficacy and enhances sustained effects. Yes.
Furthermore, compared with the non-chewable tablet D, the preparation of the present invention has a significantly improved improvement rate after 10 minutes and is excellent in the improvement rate after 4 hours, and has both immediate effect and sustainability. I understand that.
From the above results, the dissolution type and chewable type preparations of the present invention are immediate effects as compared with the preparations of the same dosage form not containing menthol and normal tablets containing menthol, and have a sustained effect. It is clear that Even after 4 hours from administration, the composition of the present invention exhibits a high effect as compared with the corresponding tablet. Therefore, the composition of the present invention has a high immediate effect and a high bioavailability, and has an excellent therapeutic effect. It can be said that it is a preparation.

Test Example 3 Menthol content and effects Test preparations (GN) shown in Table 11 were used. The drug was administered to 14 subjects having nasal inflammation symptoms (sneezing, runny nose, stuffy nose, sore throat) (one tablet at a time), and the degree of improvement and irritation of the symptoms were evaluated 10 minutes after taking the drug. The test drug was chewed 5 to 15 times in the mouth.
Moreover, after each formulation was stored at room temperature for 3 months, the occurrence of whiskers was confirmed.

In Formulation G, no improvement in nasal inflammation was observed 10 minutes after administration, but in Formulations H to N, improvement in nasal inflammation was observed. However, the test drugs M and N showed mucosal irritation when taken, and the test drug N showed extremely strong mucosal irritation and a slight safety problem.
Moreover, when each preparation was stored at room temperature for 3 months and then the occurrence of whiskers was confirmed, whiskers were detected in preparations M and N. No whisker was observed in formulations G-L.

The pharmaceutical composition of the present invention is easy to take both in dosage form and taste, is effective in improving compliance, is stable with suppressed whisker expression, has excellent elution and absorption in the gastrointestinal tract, and the same. A sufficiently high bioavailability can be achieved compared to conventional oral tablets containing a quantity of active ingredient. As a result, the drug can be effectively used, and the burden on the patient can be reduced and the quality of life can be improved by reducing the dose.

Claims (1)

Mouth-dissolving or chewing type solid oral pharmaceutical composition comprising (a) a bitter-tasting drug and (b) 0.1-2.25% by weight of menthol [provided that (a) a bitter-tasting drug As chlorpheniramine maleate, isothipentyl hydrochloride, promethazine hydrochloride, promethazine methylene disalicylate, carbinoxamine, astemizole, clemastine fumarate, mequitazine, diphenhydramine hydrochloride, diphenhydramine tannic acid diphenhydramine, diphenhydramine, ibudilastofen hexothifen , Alimemazine tartrate, tranilast, potassium pemirolast, azelastine hydrochloride, oxatomide, emedastine fumarate, epinastine hydrochloride, phenylpropanolamine hydrochloride, salt Phenylephrine, methylephedrine hydrochloride, ephedrine hydrochloride, methoxyphenamine hydrochloride, norepinephrine, naphazoline nitrate, gyrometazoline, middolin, methoxamine, tetrahydrozoline, belladonna total alkaloid, datsura extract, belladonna alkaloid, belladonna extract, funnel extract, iodopropamide, Except when containing at least one selected from the group consisting of anhydrous caffeine and sodium caffeine benzoate].